- Home
- DX vs MYGN Comparison
DX vs MYGN Comparison
Compare DX & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DX
- MYGN
- Stock Information
- Founded
- DX 1987
- MYGN 1991
- Country
- DX United States
- MYGN United States
- Employees
- DX N/A
- MYGN N/A
- Industry
- DX Real Estate Investment Trusts
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- DX Real Estate
- MYGN Health Care
- Exchange
- DX Nasdaq
- MYGN Nasdaq
- Market Cap
- DX 1.1B
- MYGN 1.3B
- IPO Year
- DX N/A
- MYGN 1995
- Fundamental
- Price
- DX $12.97
- MYGN $8.70
- Analyst Decision
- DX Buy
- MYGN Hold
- Analyst Count
- DX 6
- MYGN 15
- Target Price
- DX $13.33
- MYGN $21.37
- AVG Volume (30 Days)
- DX 3.5M
- MYGN 894.0K
- Earning Date
- DX 04-21-2025
- MYGN 05-06-2025
- Dividend Yield
- DX 13.90%
- MYGN N/A
- EPS Growth
- DX N/A
- MYGN N/A
- EPS
- DX 1.49
- MYGN N/A
- Revenue
- DX $150,396,000.00
- MYGN $837,600,000.00
- Revenue This Year
- DX N/A
- MYGN $2.97
- Revenue Next Year
- DX $8.64
- MYGN $8.37
- P/E Ratio
- DX $8.74
- MYGN N/A
- Revenue Growth
- DX 462.25
- MYGN 11.21
- 52 Week Low
- DX $11.36
- MYGN $8.53
- 52 Week High
- DX $14.52
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- DX 30.99
- MYGN 28.26
- Support Level
- DX $12.89
- MYGN $8.53
- Resistance Level
- DX $14.50
- MYGN $10.30
- Average True Range (ATR)
- DX 0.24
- MYGN 0.46
- MACD
- DX -0.16
- MYGN -0.01
- Stochastic Oscillator
- DX 7.14
- MYGN 19.08
About DX Dynex Capital Inc.
Dynex Capital Inc is an internally managed mortgage real estate investment trust, which invests in mortgage-backed securities. The company invests in residential and commercial mortgage-backed securities. Its objective is to provide attractive risk-adjusted returns to shareholders over the long term that are reflective of a leveraged, high quality fixed income portfolio with a focus on capital preservation. Its investments consist principally of Agency mortgage-backed securities including residential MBS and commercial MBS.
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.